Table 4 Subgroup analysis
Subgroup | No. of studies | No. of patients | RR (95% CI) | SEN (95% CI) | SPE (95% CI) | Test for heterogeneity (I2) |
|---|---|---|---|---|---|---|
All studies | ||||||
qSOFA | 8 | 52,849 | 4.55 (3.38–6.14) | 0.42 (0.31–0.54) | 0.88 (0.83–0.92) | 91.1 |
SIRS | 8 | 52,849 | 2.75 (1.96–3.86) | 0.81 (0.75–0.86) | 0.41 (0.32–0.50) | 89 |
Prospective studies | ||||||
qSOFA | 4 | 11,122 | 5.34 (4.19–6.82) | 0.39 (0.22–0.60) | 0.90 (0.83–0.94) | 37.2 |
SIRS | 4 | 11,122 | 3.23 (1.95–4.33) | 0.80 (0.67–0.89) | 0.47 (0.38–0.56) | 78.5 |
Retrospective studies | ||||||
qSOFA | 4 | 41,727 | 3.95 (2.48–6.44) | 0.44 (0.38–0.50) | 0.85 (0.80–0.90) | 86.2 |
SIRS | 4 | 41,727 | 2.35 (1.40–3.93) | 0.83 (0.78–0.87) | 0.34 (0.21–0.49) | 84.4 |
In-hospital mortality | ||||||
qSOFA | 5 | 41,372 | 4.20 (3.18–5.56) | 0.49 (0.41–0.57) | 0.84 (0.81–0.86) | 86.6 |
SIRS | 5 | 41,372 | 2.97 (1.84–4.80) | 0.85 (0.81–0.88) | 0.35 (0.25–0.46) | 81.8 |
30-day mortality | ||||||
qSOFA | 3 | 11,477 | 5.22 (2.70–10.07) | 0.41 (0.37–0.46) | 0.92 (0.92–0.93) | 84.1 |
SIRS | 3 | 11,477 | 2.42 (1.40–4.23) | 0.74 (0.69–0.78) | 0.54 (0.53–0.55) | 81.4 |
The initial values | ||||||
qSOFA | 5 | 35,462 | 3.29 (2.51–4.29) | 0.33 (0.22–0.47) | 0.90 (0.82–0.94) | 79.1 |
SIRS | 5 | 35,462 | 1.93 (1.20–3.15) | 0.78 (0.68–0.86) | 0.37 (0.25–0.51) | 92.1 |
The worst values | ||||||
qSOFA | 3 | 17,387 | 6.89 (5.12–9.27) | 0.55 (0.47–0.63) | 0.87 (0.82–0.90) | 71 |
SIRS | 3 | 17,387 | 4.24 (3.50–5.14) | 0.85 (0.75–0.91) | 0.46 (0.35–0.57) | 0 |